Evusheld Survey: New treatment to prevent COVID-19 infection in people with poor immune systems |
A new preventative therapy has been developed to protect those with weakened immune systems from COVID-19 infection. The treatment is given pre-exposure to the virus, which means it cannot be given to someone who has recently been exposed to the virus through contact with an infected person or someone who later tests positive for COVID-19. Clinical trials found that the treatment reduced the risk of developing symptomatic COVID-19 by 77%, with protection lasting for up to six months.
Before this treatment can routinely be used in those with weakened immune systems, it requires approval or market authorisation via the National Institute of Health and Clinical Excellence (NICE). NICE, as part of this process, are carrying out an assessment of the potential clinical and cost effectiveness of this drug and are keen to gather the views of various stakeholders such as professional bodies, NHS commissioning organisations, and patient groups. NICE wants to understand the condition and current treatments from the patient perspective to establish the benefits that any new treatment could make to the lives of people who live with scleroderma.
Through this survey SRUK hope to gain insight from our patient community, to ensure that the feedback we offer NICE is accurate and relevant. It should take no more than 10 minutes of your time.
The deadline for completion is 00.01am, Tuesday 13th September 2022.
Survey responses are anonymous, the data will be viewed by SRUK to inform our report to NICE.
If you have any questions relating to the survey, please contact info@sruk.co.uk.
Thank you for your participation!